PURPOSE: Lycopene is thought to decrease the risk of cancers, although previous epidemiologic studies have produced inconsistent results. The aim of the present study was to evaluate the protective effect of lycopene against the risk of cancer. METHODS: The study population consisted of 997 middle-aged Finnish men in the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) cohort. During the mean follow-up time of 12.6 years, a total of 141 cancer cases appeared, of which 55 were prostate cancers. The association between the serum concentrations of lycopene and the risk of cancer was studied using the Cox proportional hazard models. RESULTS: An inverse association was observed between serum lycopene and overall cancer incidence. The adjusted risk ratio (RR) in the highest tertile of serum lycopene was 0.55 (95% confidence interval [CI], 0.34-0.89; p=0.015) compared with the lowest serum lycopene group. No association was observed between the lycopene concentrations and a prostate cancer risk. RR for other cancers was 0.43 (95% CI, 0.23-0.79; p=0.007). CONCLUSIONS: These findings suggest that in middle-aged men, the higher circulating concentrations of lycopene may contribute to the lower risk of cancer, with the exception of prostate cancer.
PURPOSE:Lycopene is thought to decrease the risk of cancers, although previous epidemiologic studies have produced inconsistent results. The aim of the present study was to evaluate the protective effect of lycopene against the risk of cancer. METHODS: The study population consisted of 997 middle-aged Finnish men in the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) cohort. During the mean follow-up time of 12.6 years, a total of 141 cancer cases appeared, of which 55 were prostate cancers. The association between the serum concentrations of lycopene and the risk of cancer was studied using the Cox proportional hazard models. RESULTS: An inverse association was observed between serum lycopene and overall cancer incidence. The adjusted risk ratio (RR) in the highest tertile of serum lycopene was 0.55 (95% confidence interval [CI], 0.34-0.89; p=0.015) compared with the lowest serum lycopene group. No association was observed between the lycopene concentrations and a prostate cancer risk. RR for other cancers was 0.43 (95% CI, 0.23-0.79; p=0.007). CONCLUSIONS: These findings suggest that in middle-aged men, the higher circulating concentrations of lycopene may contribute to the lower risk of cancer, with the exception of prostate cancer.
Authors: Alan R Kristal; Cathee Till; Elizabeth A Platz; Xiaoling Song; Irena B King; Marian L Neuhouser; Christine B Ambrosone; Ian M Thompson Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-02-18 Impact factor: 4.254
Authors: Ke Zu; Lorelei Mucci; Bernard A Rosner; Steven K Clinton; Massimo Loda; Meir J Stampfer; Edward Giovannucci Journal: J Natl Cancer Inst Date: 2014-01-24 Impact factor: 13.506
Authors: Timothy J Key; Paul N Appleby; Ruth C Travis; Demetrius Albanes; Anthony J Alberg; Aurelio Barricarte; Amanda Black; Heiner Boeing; H Bas Bueno-de-Mesquita; June M Chan; Chu Chen; Michael B Cook; Jenny L Donovan; Pilar Galan; Rebecca Gilbert; Graham G Giles; Edward Giovannucci; Gary E Goodman; Phyllis J Goodman; Marc J Gunter; Freddie C Hamdy; Markku Heliövaara; Kathy J Helzlsouer; Brian E Henderson; Serge Hercberg; Judy Hoffman-Bolton; Robert N Hoover; Mattias Johansson; Kay-Tee Khaw; Irena B King; Paul Knekt; Laurence N Kolonel; Loic Le Marchand; Satu Männistö; Richard M Martin; Haakon E Meyer; Alison M Mondul; Kristin A Moy; David E Neal; Marian L Neuhouser; Domenico Palli; Elizabeth A Platz; Camille Pouchieu; Harri Rissanen; Jeannette M Schenk; Gianluca Severi; Meir J Stampfer; Anne Tjønneland; Mathilde Touvier; Antonia Trichopoulou; Stephanie J Weinstein; Regina G Ziegler; Cindy Ke Zhou; Naomi E Allen Journal: Am J Clin Nutr Date: 2015-10-07 Impact factor: 7.045